SCHEMBL2903706

SCHEMBL2903706

Cc1sc2nc(Cl)cc(C(N)c3ccccn3)c2c1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
ALDH1A1 P00352 5/20 0.43
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 2/20 0.42
RXFP1 Q9HBX9 1/20 0.40
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.38
PRKCI P41743 2/20 0.37
CHRM4 P08173 1/20 0.37
FGFR1 P11362 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CSNK2A2 P19784 2/20 0.33
CSNK2B P67870 2/20 0.33
CSNK2A1 P68400 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897018 0.78 LMNA (0.49) SMN1; SMN2HTTALDH1A1HPGDNPC1
SCHEMBL2905390 0.76 ALDH1A1 (0.53) SMN1; SMN2HTTATMALDH1A1HPGD
SCHEMBL3384558 0.75 FGFR1 (0.46) SMN1; SMN2HTTATMALDH1A1HPGD
SCHEMBL2903707 0.71 KDM4E (0.44) SMN1; SMN2HTTATMALDH1A1HPGD
SCHEMBL2903658 0.70 LMNA (0.43) SMN1; SMN2HTTALDH1A1HPGDNPC1
SCHEMBL2368819 0.68 CHRM4 (0.36) SMN1; SMN2HTTATMCHRM4
SCHEMBL2369505 0.65 ALDH1A1 (0.64) SMN1; SMN2HTTATMALDH1A1HPGD
SCHEMBL12600823 0.64 ALDH1A1 (0.51) SMN1; SMN2HTTATMALDH1A1HPGD
SCHEMBL14677363 0.64 SMN1; SMN2 (0.40) SMN1; SMN2HTTNPC1L3MBTL1LMNA
SCHEMBL71309 0.64 RXFP1 (0.79) SMN1; SMN2HTTATMALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193215-B2 Thieno[2 3-b]pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2012-06-05 US disclosed
EP-1879899-B1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-08-04 EP disclosed
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors XENTION LIMITED (GB) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors SCN8A, SCN1B, SCN2B SMN1; SMN2 3608/4885HTT 3498/4885ATM 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.